0
settings
الوضع الليلي
moon
انماط الصفحة الرئيسية arrow
EN
1
المرجع الالكتروني للمعلوماتية

النبات

مواضيع عامة في علم النبات

الجذور - السيقان - الأوراق

النباتات الوعائية واللاوعائية

البذور (مغطاة البذور - عاريات البذور)

الطحالب

النباتات الطبية

الحيوان

مواضيع عامة في علم الحيوان

علم التشريح

التنوع الإحيائي

البايلوجيا الخلوية

الأحياء المجهرية

البكتيريا

الفطريات

الطفيليات

الفايروسات

علم الأمراض

الاورام

الامراض الوراثية

الامراض المناعية

الامراض المدارية

اضطرابات الدورة الدموية

مواضيع عامة في علم الامراض

الحشرات

التقانة الإحيائية

مواضيع عامة في التقانة الإحيائية

التقنية الحيوية المكروبية

التقنية الحيوية والميكروبات

الفعاليات الحيوية

وراثة الاحياء المجهرية

تصنيف الاحياء المجهرية

الاحياء المجهرية في الطبيعة

أيض الاجهاد

التقنية الحيوية والبيئة

التقنية الحيوية والطب

التقنية الحيوية والزراعة

التقنية الحيوية والصناعة

التقنية الحيوية والطاقة

البحار والطحالب الصغيرة

عزل البروتين

هندسة الجينات

التقنية الحياتية النانوية

مفاهيم التقنية الحيوية النانوية

التراكيب النانوية والمجاهر المستخدمة في رؤيتها

تصنيع وتخليق المواد النانوية

تطبيقات التقنية النانوية والحيوية النانوية

الرقائق والمتحسسات الحيوية

المصفوفات المجهرية وحاسوب الدنا

اللقاحات

البيئة والتلوث

علم الأجنة

اعضاء التكاثر وتشكل الاعراس

الاخصاب

التشطر

العصيبة وتشكل الجسيدات

تشكل اللواحق الجنينية

تكون المعيدة وظهور الطبقات الجنينية

مقدمة لعلم الاجنة

الأحياء الجزيئي

مواضيع عامة في الاحياء الجزيئي

علم وظائف الأعضاء

الغدد

مواضيع عامة في الغدد

الغدد الصم و هرموناتها

الجسم تحت السريري

الغدة النخامية

الغدة الكظرية

الغدة التناسلية

الغدة الدرقية والجار الدرقية

الغدة البنكرياسية

الغدة الصنوبرية

مواضيع عامة في علم وظائف الاعضاء

الخلية الحيوانية

الجهاز العصبي

أعضاء الحس

الجهاز العضلي

السوائل الجسمية

الجهاز الدوري والليمف

الجهاز التنفسي

الجهاز الهضمي

الجهاز البولي

المضادات الميكروبية

مواضيع عامة في المضادات الميكروبية

مضادات البكتيريا

مضادات الفطريات

مضادات الطفيليات

مضادات الفايروسات

علم الخلية

الوراثة

الأحياء العامة

المناعة

التحليلات المرضية

الكيمياء الحيوية

مواضيع متنوعة أخرى

الانزيمات

قم بتسجيل الدخول اولاً لكي يتسنى لك الاعجاب والتعليق.

Lineage-Specific Features of Leukemic Lymphoblasts

المؤلف:  Hoffman, R., Benz, E. J., Silberstein, L. E., Heslop, H., Weitz, J., & Salama, M. E.

المصدر:  Hematology : Basic Principles and Practice

الجزء والصفحة:  8th E , P1049-1050

2026-11-17

37

+

-

20

 Malignant lymphoblasts share many of the features of normal lymphoid progenitors. Thus, ALL cells rearrange their Ig and TCR genes and express components of antigen receptor molecules and other differentiation-linked cell-surface glycoproteins in ways that correspond to features of developing normal B and T lymphocytes. In some cases, leukemic cells appear to represent the clonal expansion of a lymphoid progenitor that has arrested its development at an early stage of B- or T-cell differentiation, while in others, the blast cell phenotypes differ from those of normal lymphocyte progenitors, which is likely a result of aberrant regulation of gene expression. Still, the general concept that leukemic cells should be classified according to their “normal” developmental stage remains an important one, providing a basis for the study of immunophenotype-specific genetic changes.

Mature B-Cell Acute Lymphoblastic Leukemia

The diagnosis of mature B-cell ALL, also termed Burkitt leukemia, is based on the detection of surface Ig on leukemic blasts. This rare phenotype accounts for only 2% to 3% of ALL cases, and the lymphoblasts often have distinctive morphology, with deeply basophilic cytoplasm containing prominent vacuoles; this morphologic pattern was designated L3 in the French-American-British (FAB) system. Mature B-cell ALL is a disseminated form of Burkitt lymphoma, as these conditions share common cytogenetic, molecular, phenotypic, and clinical features. Mature B-cell ALL does not respond well to chemotherapy traditionally used for childhood ALL. However, favorable outcomes have been obtained with treatments designed for Burkitt lymphoma, which involves therapy of greater intensity and shorter duration. Thus, mature B-cell leukemia was the first subtype of ALL to be recognized as a distinct clinical entity based on immunophenotypic and cytogenetic features and the first to be treated by separate protocols designed specifically for the leukemia’s unique features.

B-Cell Acute Lymphoblastic Leukemia

 Approximately 80% of ALL patients have lymphoblasts with phenotypes corresponding to those of B-cell progenitors. These cases can be identified on the basis of cell-surface expression of CD19 and at least one other recognized B lineage–associated antigen: CD20, CD24, CD22, CD21, or CD79. The most common subtype of B-cell ALL, previously termed common precursor B-cell ALL, also expresses CD10. These lymphoblasts may also express nuclear terminal deoxynucleotidyl transferase (TdT) or CD34. About one-fourth of B-cell ALL cases express cytoplasmic Ig μ heavy-chain proteins and were historically designated pre-B-ALL.

DNA rearrangement of Ig genes occurs before heavy-chain gene expression in B-cell development, providing a genetic marker of B-lymphocyte ontogeny. Korsmeyer and colleagues pioneered the use of heavy- and light-chain gene rearrangements to support an early B-lineage origin of most ALL blasts. However, Ig heavy-chain gene rearrangements are observed in about 15% of T-cell ALL cases and in a similar percentage of AML cases. Thus, caution must be exercised when assigning cell lineage on the basis of studies of Ig gene rearrangement.

The identification of specific immunophenotypic, genetic, and clinical features that predict response to therapy in patients with B-lineage ALL and the use of these predictors to stratify intensity of therapy are now common features of contemporary ALL treatment protocols. This ability to predict outcome has been closely tied to the remarkable improvements in therapy for children with this disease, which 60 years ago was universally fatal. However, many subgroups of pediatric and adult patients continue to face a poor prognosis, and much progress remains to be made.

T-Cell Acute Lymphoblastic Leukemia

Lymphoblasts with a T-cell phenotype, defined by the WHO as cell-surface expression of TdT with variable expression of CD1a, CD2, CD3, CD4, CD5, CD7, and CD8, comprise approximately 15% of cases of childhood ALL and a higher proportion of ALL in adults. These cases can be further classified according to the sequence of expression of T-cell-associated surface antigens during normal thymocyte ontogeny. Numerous investigators, using a battery of monoclonal antibodies specific for T-cell surface glycoproteins, have confirmed the close relationship between the recognizable patterns of surface antigen expression on leukemic T cells and the normal stages of thymocyte development. T-cell ALL is often associated with distinctive clinical features that include high circulating leukocyte counts, male predominance, central nervous system involvement, and a radiographically evident thymic mass in many cases at presentation. Historically, patients with T-cell ALL had an adverse prognosis compared with patients with B-cell ALL; however, with contemporary therapy, outcomes are similar. In marked con trast to B-cell ALL, in which the availability of a wide range of clinical and genetic prognostic markers has allowed the development of treatment protocols tailored to an individual patient’s risk of relapse, robust pretreatment prognostic markers are lacking in T-cell ALL. Recent discovery of biomarkers of differentiation arrest at the earliest stages of T-cell development has identified potential markers of treatment resistance.

A distinctive subset of T-cell ALL has been identified that is associated with an increased risk of slow early response and/or early treatment failure, the so-called early T-cell precursor (ETP) subset of T-cell ALL. ETP ALL comprises 8% to 15% of pediatric T-ALL cases but accounts for a much higher fraction of T-cell ALL in adults and is characterized by differentiation arrest at the earliest identifiable stages of T-cell development. These cases are most commonly identified by a specific immunophenotype, which can be defined by the lack of expression of the T-lineage cell-surface markers CD1a and CD8, weak or absent expression of CD5, and aberrant expression of one or more myeloid or stem cell markers. ETP cases also express a distinctive gene expression profile and often have an absence of biallelic TCRγ deletion (ABD), indicating differentiation arrest prior to the completion of TCR gene rearrangement. In addition to harboring oncogenic lesions typical of T-cell ALL, ETP cases also harbor gene mutations that are characteristic of acute myeloid leukemia, including mutations of Polycomb repressive complex 2 (PRC2) genes (EZH2, EED, or SUZ12) and WT1 mutations, suggesting that the cell of origin of ETP leukemia may be a multipotent hematopoietic stem or progenitor cell rather than a committed T-cell progenitor. Evidence also indicates that a subset of AML cases have features characteristic of T-cell differentiation, suggesting that current WHO classification schemes may have resulted in the separation of a biologically unique entity with features of both T-lymphoblastic and myeloid differentiation across the T-cell ALL, AML, and mixed-phenotype acute leukemia (MPAL) diagnostic categories. The term acute myeloid/T lymphoblastic leukemia has been proposed for this entity, although defining the optimal therapeutic approach for these cases requires additional investigation.

Mixed-Phenotype Acute Leukemia

MPAL defines a heterogenous class of leukemias in which blast cells coexpress antigens of both lymphoid and myeloid lineage. Historically, two distinct forms of these leukemias have been rec ognized: biphenotypic leukemia, which accounts for the majority of MPAL and can be the result of cells coexpressing B-cell or T-cell antigens together with myeloid-associated antigen (B/myeloid MPAL and T/myeloid MPAL, respectively), or more rarely cells that coexpress B-cell and T-cell antigens (B/T MPAL) or B-cell, T-cell, and myeloid antigens (B/T/myeloid MPAL), and bilineal leukemia, in which there are two distinct populations of cells (generally one lymphoid and one myeloid). Despite recent work investing the com plex genomic and epigenomic landscape of MPAL, the origin of this subtype remains unknown. One possibility is the malignant trans formation of pluripotent hematopoietic stem or progenitor cells that retain the ability to differentiate in both the myeloid and lymphoid lineages; another is the immortalization of rare progenitor cells that normally coexpress features of both lineages; and a third is aberrant gene expression caused by specific genetic alterations. Despite initial controversy, co-expression of myeloid antigens in ALL, or of lymphoid markers in acute myeloid leukemia, does not appear to have prognostic significance in the setting of contemporary treatment regimens.

اخر الاخبار

اشترك بقناتنا على التلجرام ليصلك كل ما هو جديد